Post-Trastuzumab ADCs like Enhertu, along with emerging bispecific antibodies and CAR‑T cell constructs targeting HER2, are reshaping the treatment landscape https://www.einpresswire.com/article/833965726/her2-gastric-cancer-therapy-market-set-for-steady-growth-by-2033-datam-intelligence